Drug Information

Drug (ID: DG01855) and It's Reported Resistant Information

• Name: HG-6-63-01
• Synonyms: HG-6-63-01
• Target: .; NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Solid tumour/cancer [ICD-11: 2A00-2F9Z]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Proto-oncogene tyrosine-protein kinase receptor Ret (RET) [1]

• Molecule Alteration: Missense mutation; p.C634Y (c.1901G>A)
• Sensitive Disease: Solid tumour/cancer [ICD-11: 2A00-2F9Z]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: TT cells; Thyroid gland; Homo sapiens (Human); CVCL_1774
• In Vitro Model: RET/V804M cells; Bone marrow; Mus musculus (Mouse); CVCL_XZ26
• In Vitro Model: RET/V804L cells; N.A.; Mus musculus (Mouse); CVCL_XZ25
• In Vitro Model: RET/S891A cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/M918T cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/M918T cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/L790F cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/E768D cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/C634R cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/C634R cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/A883F cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: MZ-CRC-1 cells; Pleural effusion; Homo sapiens (Human); CVCL_A656
• In Vitro Model: RET/V804M cells; Bone marrow; Mus musculus (Mouse); CVCL_XZ26
• In Vitro Model: RET/E768D cells; N.A.; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: Cell counting assay

Key Molecule: Proto-oncogene tyrosine-protein kinase receptor Ret (RET) [1]

• Molecule Alteration: Missense mutation; p.M918T (c.2753T>C)
• Sensitive Disease: Solid tumour/cancer [ICD-11: 2A00-2F9Z]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: TT cells; Thyroid gland; Homo sapiens (Human); CVCL_1774
• In Vitro Model: RET/V804M cells; Bone marrow; Mus musculus (Mouse); CVCL_XZ26
• In Vitro Model: RET/V804L cells; N.A.; Mus musculus (Mouse); CVCL_XZ25
• In Vitro Model: RET/S891A cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/M918T cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/M918T cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/L790F cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/E768D cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/C634R cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/C634R cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/A883F cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: MZ-CRC-1 cells; Pleural effusion; Homo sapiens (Human); CVCL_A656
• In Vitro Model: RET/V804M cells; Bone marrow; Mus musculus (Mouse); CVCL_XZ26
• In Vitro Model: RET/E768D cells; N.A.; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: Cell counting assay

Thyroid cancer [ICD-11: 2D10]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Proto-oncogene tyrosine-protein kinase receptor Ret (RET) [1]

• Molecule Alteration: Missense mutation; p.C634W (c.1902C>G)
• Sensitive Disease: Thyroid gland cancer [ICD-11: 2D10.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: TT cells; Thyroid gland; Homo sapiens (Human); CVCL_1774
• In Vitro Model: RET/V804M cells; Bone marrow; Mus musculus (Mouse); CVCL_XZ26
• In Vitro Model: RET/V804L cells; N.A.; Mus musculus (Mouse); CVCL_XZ25
• In Vitro Model: RET/S891A cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/M918T cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/M918T cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/L790F cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/E768D cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/C634R cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/C634R cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/A883F cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: MZ-CRC-1 cells; Pleural effusion; Homo sapiens (Human); CVCL_A656
• In Vitro Model: RET/V804M cells; Bone marrow; Mus musculus (Mouse); CVCL_XZ26
• In Vitro Model: RET/E768D cells; N.A.; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: Cell counting assay

Key Molecule: Proto-oncogene tyrosine-protein kinase receptor Ret (RET) [1]

• Molecule Alteration: Missense mutation; p.M918T (c.2753T>C)
• Sensitive Disease: Thyroid gland cancer [ICD-11: 2D10.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: TT cells; Thyroid gland; Homo sapiens (Human); CVCL_1774
• In Vitro Model: RET/V804M cells; Bone marrow; Mus musculus (Mouse); CVCL_XZ26
• In Vitro Model: RET/V804L cells; N.A.; Mus musculus (Mouse); CVCL_XZ25
• In Vitro Model: RET/S891A cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/M918T cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/M918T cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/L790F cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/E768D cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/C634R cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/C634R cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: RET/A883F cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: MZ-CRC-1 cells; Pleural effusion; Homo sapiens (Human); CVCL_A656
• In Vitro Model: RET/V804M cells; Bone marrow; Mus musculus (Mouse); CVCL_XZ26
• In Vitro Model: RET/E768D cells; N.A.; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: Cell counting assay

References

• Ref 1: Identification of Novel Small Molecule Inhibitors of Oncogenic RET KinasePLoS One. 2015 Jun 5;10(6):e0128364. doi: 10.1371/journal.pone.0128364. eCollection 2015.